Key points are not available for this paper at this time.
This study identifies baseline TI-NK cells as an independent biomarker with great predictive value for pCR to anti-HER2 antibody-based treatment and points to the complementary value of tumor HLA-I status for defining patient prognosis independently of pCR.
Muntasell et al. (Wed,) studied this question.